Erythropoietin: high profile, high scrutiny.
Crawford
Jeffrey
J
D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy* / Q000209:etiology*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006397:Hematinics / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000401:mortality; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D011994:Recombinant Proteins; D012107:Research Design; D018570:Risk Assessment; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa